# OnCo record vididencel (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/vididencel/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "vididencel" ;
  schema:name "Vididencel"@en ;
  schema:alternateName "DCP-001"@en, "DCOne"@en ;
  schema:description "Vididencel is an experimental allogeneic cell-based active immunotherapy, given intradermally from Mendus, in phase 2 trials for acute myeloid leukaemia, chronic myeloid leukaemia and high-risk ovarian cancer."@en ;
  schema:url <https://onco.cc/drugs/vididencel/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.mendus.com/what-we-do/>, <https://www.mendus.com/what-we-do/>, <https://www.mendus.com/what-we-do/>, <https://stockanalysis.com/quote/sto/IMMU/company/>, <https://clinicaltrials.gov/search?intr=DCP-001> ;
  onco:status "phase-2" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Allogeneic cell-based active immunotherapy (dendritic cell vaccine from a leukaemia cell line), given intradermally" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/ovarian/> ;
  onco:companies <https://onco.cc/companies/mendus/> ;
  onco:trials <https://onco.cc/trials/nct03697707/>, <https://onco.cc/trials/nct01373515/>, <https://onco.cc/trials/nct04739527/>, <https://onco.cc/trials/nct07651878/> .